Sold as Manganese Chloride In Plastic Container. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Manganese Chloride (sold as Manganese Chloride In Plastic Container), first approved Jun 26, 1986, with 0 new uses approved and 0 published complete response letters.
| A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian CancerOvarian Cancer · Chinese PLA General Hospital | Phase 3 | Recruiting | Sep 16, 2026 |
| Effect of Probiotics After NeurosurgeryHealing · University Maribor | Not applicable | Recruiting | Oct 1, 2025 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck CancerClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · NRG Oncology | Phase 2 | Recruiting | Aug 1, 2024 |
| Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's DiseaseParkinson Disease, Depression · University of British Columbia | Phase 2 | Recruiting | Oct 5, 2022 |
| Jun 26, 1986 | Manganese Chloride In Plastic ContainerNDA 18962 | Hospira | 11 | Marketed |
| Jul 7, 2025 | Manganese ChlorideANDA 217583 | Fresenius Kabi USA | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Fresenius Kabi USA